Please login to the form below

Not currently logged in
Email:
Password:

BMS wins first US immuno-oncology paediatric licence

FDA gives the green light to expanded use of its melanoma treatment Yervoy

BMSBristol-Myers Squibb has won the first paediatric indication for an immuno-oncologydrug in the US.

The Food and Drug Administration (FDA) approved an expanded licence for Yervoy (ipilimumab) that will allow its use to treat unresectable or metastatic melanoma in patients aged 12 and older.

Chris Boerner, president and head of US commercial operations, BMS, said: “Despite significant advancements in oncology research for adults in recent years, treatment options continue to be limited for paediatric patients with metastatic melanoma.

“This latest approval of Yervoy exemplifies our on-going effort to expand the availability of therapies for younger cancer patients.”

After running two trials in paediatric patients BMS found the overall safety profile for children and adolescents of Yervoy, which was first approved in the US in 2011, was consistent with that for adults.

The studies involved two groups totalling of 45 patients - one ranging from two to 21 years old and the other ranging from two to 16 - being administered a 3mg/kg dose of ipilimumab intravenously for over 90 minutes every three weeks, for a total of four doses.

Lia Gore, managing director of the University of Colorado School of Medicine and Children’s Hospital of Colorado, said: “Metastatic Melanoma is extremely rare in children and adolescents, which makes it particularly difficult to investigate in clinical trials.

“Ipilimumab’s approval represents the culmination of a long effort and gives physicians the ability to expand immuno-oncology - one of the most exciting areas of medicine - for the treatment of young adults with metastatic melanoma.”

The approval comes at an essential time for the New York, US-based group, as the medicine received a knock-back from its own Opdivo (nivolumab) in adjuvant melanoma therapy, which led analysts at EvaluatePharma to predict that Merck & Co’s melanoma drug Keytruda (pembrolizumab) will topple Opdivo as the top-selling PD-1/PD-L1 inhibitor by 2022.

Article by
Gemma Jones

25th July 2017

From: Regulatory

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...

Infographics